What we do Godavari Drugs Ltd manufactures Active Pharmaceutical Ingredients, drug intermediates, and fine chemicals serving the global life sciences industry from its plant in Maharashtra, India. |
Founded in 1,987 |
Market share Not a market leader but established exporter of key antibacterial API Sulphamethoxazole with growing backward integration. |
Problem solved Provides critical APIs like Sulphamethoxazole and Trimetroprim used in antibacterial treatments, ensuring quality raw materials for global pharma. |
Top clients or who we serve Serves pharmaceutical companies globally, including loan license manufacturing for reputed multinational firms; primarily B2B. |
Key management - |
Our journey and innovations Established in 1987, expanded SMX capacity and backward integrated to produce intermediates enhancing product value; diversified into TMP and new APIs. |
Where we operate Primarily India with exports to global life sciences and pharmaceutical markets. |
Top products or what we offer Sulphamethoxazole (SMX), Sulphamethoxide (SMO), Diethyl Oxalate (DEO), Trimetroprim (TMP), and Pyrazyamide APIs with growing production capacities. |
Top brands SMX - key antibacterial API with high export demand; TMP used in combination therapies; Pyrazyamide - newly introduced anti-TB drug API. |
Raw materials needed Raw materials for APIs and intermediates including chemical precursors for Sulphamethoxazole and Trimetroprim production. |
Raw materials supplier Not specified but diversified supply chain is a strategic focus to minimize disruption. |
Recurring vs cyclical contribution Revenues are mostly recurring from ongoing API sales and loan license manufacturing contracts. |
Our industry position Niche mid-sized player with backward integration enhancing margin; not a dominant market leader but focused on quality export markets. |
Financial highlights FY 2024-25 revenue Rs.113.35 crore; net profit Rs.4.38 crore; EBITDA around Rs.12.8 crore; slight decline from previous year. |
Geographical revenue split - |
Order book - |
Whats driving growth Capacity expansions, backward integration, new API launches, enhanced supply chain, and regulatory compliance fuel growth. |
Our future plans Commission new API and intermediate manufacturing facility by end FY 2025-26 to expand product portfolio and capacity. |
Our green promise Invests in energy efficiency, conducts energy audits, and supports environmental sustainability initiatives as part of CSR. |
Our people and values 106 employees with focus on empowerment, skill development, and ethical work environment fostering performance. |
Key challenges ahead Competitive API market, regulatory changes, and cost pressures demand operational efficiencies and strategic positioning. |
Interesting facts Pioneered backward integration for SMX intermediates; expanding Pyrazyamide production based on market acceptance. |
Risks and strategy Mitigates supply chain risks through diversification; complies with evolving regulations; focuses on operational and strategic agility. |
